Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Interaction of ASC18 (Ravidasvir/Sofosbuvir) in Healthy Subjects
NCT04358523Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Mar 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ravidasvir + sofosbuvir in hepatitis C (HCV) (2 arms), sponsored by Ascletis Pharma Inc. Primary endpoint: Number of Adverse Events up to 93 days. Started Mar 2020; status: completed.
02
Drugs
ravidasvir + sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04358523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358523.